Respiratory Syncytial Virus (RSV) Diagnostic Market Size (2024 - 2029)

The respiratory syncytial virus (RSV) diagnostic market is anticipated to experience substantial growth, driven by the increasing global burden of RSV infections and advancements in diagnostic technology. The market's expansion is supported by the introduction of new diagnostic products and tests, which enhance the availability and effectiveness of RSV detection. Despite challenges such as stringent regulatory requirements and the limitations of some immunoassays, the market is poised for significant growth due to strategic initiatives by key players and the rising demand for RSV testing.

Market Size of Respiratory Syncytial Virus (RSV) Diagnostic Industry

Respiratory Syncytial Virus (RSV) Diagnostic Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 10.10 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

Respiratory Syncytial Virus (RSV) Diagnostic Market Major Players

*Disclaimer: Major Players sorted in no particular order

Respiratory Syncytial Virus (RSV) Diagnostic Market Analysis

The respiratory syncytial virus (RSV) diagnostic market is expected to register a significant CAGR of 10.1% during the study period.

  • Although COVID-19 led to a shortage in essential diagnostic tests during the early pandemic, multiplex diagnostics have played an important role in providing quick results for COVID-19 diagnostics. However, the launch of products is propelling the growth of the market. For instance, in February 2022, Avellino Labs USA Inc. launched AvellinoCoV2 - Respiratory Test, a multi-panel RT-PCR-based virus assay that accurately detects four viral infections in one patient sample - COVID-19, respiratory syncytial virus (RSV), influenza A and influenza B. Thus, COVID-19 has slightly declined during the early pandemic due to lockdown restrictions. However, the market was positively impacted during the late pandemic due to a rise in testing for RSV and saw a significant surge post-pandemic due to the launch of new tests, and it is expected to boost the market's growth over the period.
  • The factors propelling the studied market growth are the growing burden of respiratory syncytial virus infections globally, rise in investments, technological advancements in the development of RSV diagnostic tests, product approvals and launches, and other key strategies adopted by the market players.
  • According to the Center for Disease Control and Prevention (CDC) update in July 2023, the overall rate of RSV-associated hospitalizations was 50.9 per 100,000 people in the United States in the 2022-2023 season. Such a huge rate of hospitalization is anticipated to increase the adoption of testing for RSV infections, driving the market growth.
  • The launch of products for the effective diagnosis of RSV infections is expected to boost the studied market growth due to the increased availability of products in the market. For instance, in November 2021, QIAGEN launched the QIAstat-Dx Respiratory 4 Plex Flu A-B/RSV/SARS-CoV-2 test for the QIAstat-Dx system to quickly identify whether patients have common seasonal respiratory infections or SARS-CoV-2. Additionally, in September 2021, Roche launched three molecular polymerase chain reaction (PCR) diagnostic test panels to detect and differentiate common respiratory pathogens at the same time, which include influenza A, influenza B, and respiratory syncytial virus (RSV); adenovirus (ADV), human metapneumovirus (hMPV) and enterovirus/rhinovirus (EV/RV); and parainfluenza 1, 2, 3 and 4.
  • Moreover, key initiatives adopted by key market players are expected to propel market growth significantly. In February 2022, Seegene Inc. signed a supply deal with the Ministry of Health of Brazil to deliver four million Allplex SARS-CoV-2/FluA/FluB/RSV Assay, capable of identifying respiratory viruses, including COVID-19, Flu A/B as well as RSV in a single test. Such steps will boost the studied market growth during the study period due to the rise in adoption.
  • Therefore, owing to factors such as the rising incidence of RSV and key initiatives adopted by the market players, the studied market is expected to grow significantly during the study period. However, strict regulatory norms and low detection limits of immunoassays are expected to hinder the market growth during the study period.

Respiratory Syncytial Virus (RSV) Diagnostic Industry Segmentation

Respiratory syncytial virus (RSV) is a virus that causes respiratory infections such as bronchiolitis and pneumonia. The symptoms of the disease usually include runny nose, sneezing, coughing, and fever.

The respiratory syncytial virus (RSV) diagnostic market is segmented by product (kits and reagents, instruments, and other products), method (molecular diagnostics, rapid antigen detection tests, immunoassays, flow cytometry, and chromatography), end-user (hospitals and clinics, clinical laboratories, and other end-users), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally.

The report offers the value (in USD) for the above-mentioned segments.

By Product
Kits and Assays
Instruments
Other Products
By Method
Molecular Diagnostics
Rapid Antigen Detection Tests
Immunoassays
Flow Cytometry
Chromatography
Other Methods
By End-User
Hospitals and Clinics
Clinical Laboratories
Other End-Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Respiratory Syncytial Virus (RSV) Diagnostic Market Size Summary

The respiratory syncytial virus (RSV) diagnostic market is poised for substantial growth, driven by a combination of increasing global RSV infections, technological advancements, and strategic initiatives by key market players. The market has experienced a resurgence post-pandemic, with the introduction of innovative diagnostic products such as multiplex RT-PCR assays that detect multiple viral infections, including RSV. This growth is further supported by the rising incidence of RSV-related hospitalizations, which is expected to enhance the adoption of diagnostic testing. The market's expansion is also fueled by significant investments in research and development, leading to the approval and launch of new diagnostic tests that improve the accuracy and speed of RSV detection.

In North America, particularly the United States, the RSV diagnostic market is expected to hold a significant share due to the high rate of RSV hospitalizations and supportive government initiatives. The region benefits from a strong presence of key market players and favorable regulatory approvals for new diagnostic products. The competitive landscape is characterized by strategic moves such as acquisitions, partnerships, and distribution agreements among major players like BioMerieux SA, Becton, Dickinson and Company, and Abbott. These dynamics, coupled with the ongoing development of rapid antigen tests and point-of-care solutions, are anticipated to drive the market's growth trajectory, despite challenges posed by regulatory hurdles and detection limitations.

Explore More

Respiratory Syncytial Virus (RSV) Diagnostic Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising Burden of Syncytial Virus Infections

      2. 1.2.2 Increasing Approvals for Syncytial Virus Diagnostic Products

    3. 1.3 Market Restraints

      1. 1.3.1 Stringent Regulations and Low Detection Limits of Immunoassays

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - in USD)

    1. 2.1 By Product

      1. 2.1.1 Kits and Assays

      2. 2.1.2 Instruments

      3. 2.1.3 Other Products

    2. 2.2 By Method

      1. 2.2.1 Molecular Diagnostics

      2. 2.2.2 Rapid Antigen Detection Tests

      3. 2.2.3 Immunoassays

      4. 2.2.4 Flow Cytometry

      5. 2.2.5 Chromatography

      6. 2.2.6 Other Methods

    3. 2.3 By End-User

      1. 2.3.1 Hospitals and Clinics

      2. 2.3.2 Clinical Laboratories

      3. 2.3.3 Other End-Users

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Respiratory Syncytial Virus (RSV) Diagnostic Market Size FAQs

The Global Respiratory Syncytial Virus (RSV) Diagnostic Market is projected to register a CAGR of 10.10% during the forecast period (2024-2029)

bioMerieux SA, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd, ThermoFisher Scientific Inc. and Abbott Laboratories are the major companies operating in the Global Respiratory Syncytial Virus (RSV) Diagnostic Market.

Respiratory Syncytial Virus (RSV) Diagnostic Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)